HCG vs PT-141: two different problems on the sexual-health side

Two of the most-searched peptides in the sexual-health category get lumped together constantly, and they shouldn't be. I get asked "should I run HCG or PT-141" almost every week, usually from a guy already on testosterone replacement who read that both peptides "help with sex" and assumes they're interchangeable. Short answer: HCG and PT-141 solve two completely different problems, and the real question is which gap you actually have.

HCG (human chorionic gonadotropin) is a glycoprotein hormone that mimics luteinizing hormone at the Leydig cells in the testes. It has nothing to do with desire. It exists to keep testosterone production and testicular volume going when the normal hypothalamic-pituitary signal has been shut off, which is exactly what happens on TRT. PT-141 (bremelanotide) is a completely different molecule with a completely different job. It's a melanocortin receptor agonist that works in the brain, not the testes or the blood vessels, and its job is to restore desire itself when the wanting has gone quiet.

What HCG actually does, and who needs it

If you're on TRT, your body senses the external testosterone and stops sending its own signal down the hypothalamic-pituitary-gonadal axis. The testes go quiet, shrink over time, and stop making the intratesticular testosterone that sperm production depends on. HCG steps in for the missing signal directly at the Leydig cell receptor, which activates the same cAMP and steroidogenesis pathway LH would trigger on its own. The practical result is that testicular volume holds and intratesticular testosterone keeps flowing, which matters most if fertility is even a maybe for you down the road.

HCG is a maintenance tool that men run because they don't want to come off TRT someday to a pair of testicles that have been offline for two years, or because they're actively trying to have kids while still on therapy. The community-typical protocol is 250 to 500 IU subcutaneous, two to three times a week, run continuously alongside TRT rather than as a standalone cycle. I see this with clients on TRT constantly: the guys who add HCG from day one keep their testicular function in a place where coming off later, or adding a fertility protocol, is a much smaller lift than for the guys who didn't.

Where HCG does touch desire is indirect. If someone's testosterone is genuinely low and that's suppressing libido, correcting the testosterone deficit can bring desire back with it. But that's a testosterone story, and if someone's testosterone is already fine, HCG won't do anything for a flat libido.

What PT-141 actually does, and who needs it

PT-141 works upstream of all of that, in the brain. It activates MC4 receptors concentrated in the medial preoptic area of the hypothalamus, the region that runs sexual motivation, and that activation triggers dopamine release in the circuitry that drives approach and wanting. The MC4R pathway itself is well mapped, and it's a fundamentally different mechanism from a PDE5 inhibitor like Viagra, which only opens blood flow once arousal is already present. PT-141 works on the signal that has to exist before the plumbing matters at all.

This is also the peptide with the stronger clinical record of the two on the desire question specifically. Two Phase 3 trials combining roughly 1,267 premenopausal women with hypoactive sexual desire disorder met both co-primary endpoints, enough for FDA approval as Vyleesi in 2019, and a follow-up integrated subgroup analysis found the benefit held consistently across age, weight, and testosterone status. A large pooled safety review across 3,500 subjects and 43 studies characterized the adverse-event profile in enough detail that a 2025 meta-analysis of female sexual dysfunction treatments lists bremelanotide among the evidence-supported options. In men, the data is Phase 2 rather than Phase 3, but it's a real signal: 342 men who had failed sildenafil showed a 33.5% response rate versus 8.5% on placebo, and a separate trial found PT-141 combined with sildenafil gave an additive benefit over either alone.

The community protocol runs well below the FDA label dose. Vyleesi is dosed at 1.75 mg, but most people I talk to in the peptide space start around 250 to 500 mcg, taken 30 to 60 minutes before activity, as needed rather than daily. The reason to start low is nausea, which shows up in roughly 40% of trial participants and is worst on the first dose. It fades fast with subsequent use, and starting low is the single best lever for avoiding it. Nausea on the first dose doesn't mean the peptide isn't working.

Cost, side-effect load, and picking between them

HCG's side-effect profile is mostly about estradiol. Because Leydig cells carry aromatase, raising testosterone with HCG can also raise estrogen, and unmonitored that can mean gynecomastia risk, so bloodwork on estradiol is part of a real protocol rather than an optional extra. It's a well-tolerated peptide at TRT-adjuvant doses when someone is actually paying attention to labs.

PT-141's side-effect load is front-loaded and dose-dependent. Nausea is the headline, along with mild flushing, headache, and a transient blood pressure bump that resolves within about half a day. None of it is dangerous for someone without uncontrolled hypertension or cardiovascular disease, and it's genuinely manageable with dose titration.

On cost, HCG is a running maintenance cost tied to however long someone stays on TRT, dosed multiple times a week continuously. PT-141 is an as-needed cost, so someone using it a few times a month spends a fraction of what continuous HCG dosing runs. That's not a reason to pick one over the other on its own, since they're not substitutes for each other, but it does mean the answer for someone asking "which one" is almost always "you might need one, the other, or both, depending on what's actually going on."

Before you write any of this down, the obligatory: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

If you're on TRT and haven't added anything for testicular preservation, that's the HCG conversation, and it's worth having with your prescriber regardless of libido. If desire specifically has gone flat and testosterone isn't the culprit, that's the PT-141 conversation. And if you're a guy on TRT with HCG already running and libido is still low, that's exactly the case where both peptides earn their place at once, because they're not competing for the same job.

For more on how TRT-adjuvant compounds fit together, see HCG and PT-141 in the full encyclopedia, and if you're weighing other paired protocols the HCG and Oxytocin comparison walks through a related decision.

Thanks for reading! In health, Rick Gold